In today’s recent session, 1.37 million shares of the Biogen Inc (NASDAQ:BIIB) have been traded, and its beta is 0.02. Most recently the company’s share price was $202.62, and it changed around $9.44 or 4.89% from the last close, which brings the market valuation of the company to $29.45B. BIIB at last check was trading at a discount to its 52-week high of $319.76, offering almost -57.81% off that amount. The share price’s 52-week low was $189.44, which indicates that the recent value has risen by an impressive 6.5% since then. We note from Biogen Inc’s average daily trading volume that its 3-month average coming to 1.20 million.

Biogen Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.60. If we narrow it down even further, the data shows that 0 out of 32 analysts rate the stock as a Sell; another 8 rate it as Overweight. Among the rest, 11 recommended BIIB as a Hold, whereas 13 deemed it a Buy, and 0 rated it as Underweight. Biogen Inc is expected to report earnings per share of $3.45 for the current quarter.

Biogen Inc (NASDAQ:BIIB) trade information

Instantly BIIB has been showing a green trend so far today with a performance of 4.89% on intraday trading today. The performance over the last five days has remained in the green territory. The company’s shares are currently down -21.70% year-to-date, but still up 5.44% over the last five days. On the other hand, Biogen Inc (NASDAQ:BIIB) is -6.49% down in the 30-day period.

The consensus price target as assigned by Wall Street analysts is $292.5, which translates to bulls needing to increase their stock price by 30.73% from its current value. Analyst projections state that BIIB is forecast to be at a low of $209 and a high of $405.

Biogen Inc (BIIB) estimates and forecasts

Biogen Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -20.04 percent over the past six months and at a 5.10% annual growth rate that is well below the industry average of 12.90%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 1.50% in revenue this quarter, and will report a decrease of -2.00% in the next quarter. The year-over-year growth rate is expected to be -4.00%, down from the previous year.

Consensus estimates provided by 28 financial analysts predict the company will bring in an average of $2.31 billion in revenue for the current quarter. 24 analysts expect Biogen Inc to make $2.37 billion in revenue for the quarter ending Jun 2024. The company’s sales for the same quarters a year ago were $2.34 billion and $2.37 billion respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -1.30%. Forecasts for the next quarter put sales growth at 0.20%.

Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -18.05%. Biogen Inc earnings are expected to increase by 5.24% in 2024, but the outlook is positive 2.80% per year for the next five years.